- Home
- ACIU vs CD Comparison
ACIU vs CD Comparison
Compare ACIU & CD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | CD |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.6M | 227.2M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACIU | CD |
|---|---|---|
| Price | $2.69 | $3.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 223.6K | ★ 253.1K |
| Earning Date | 05-12-2026 | 08-31-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,867,068.00 |
| Revenue This Year | $706.75 | N/A |
| Revenue Next Year | $321.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.93 |
| 52 Week Low | $2.04 | $2.10 |
| 52 Week High | $4.00 | $14.10 |
Technical Indicators
Market Signals| Indicator | ACIU | CD |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 51.80 |
| Support Level | $2.57 | $2.96 |
| Resistance Level | $3.13 | $4.28 |
| Average True Range (ATR) | 0.17 | 0.53 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 55.46 | 48.96 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.